Market Trends of Pregabalin Industry
Neuropathic Pain Application Segment is Expected to Occupy Significant Share in the Market During the Forecast Period
Neuropathic pain is a type of pain that is frequently persistent, and it typically results from a chronic, progressive nerve illness. However, it can also be brought on by an injury or an infection. An incident or injury does not frequently bring on the discomfort associated with neuropathic pain. Instead, the body sends pain signals to your brain unprompted. The primary causes of neuropathic pain include neuropathic pain diseases, multiple sclerosis, multiple myeloma, and diabetic neuropathy, along with injury or infection.
Pregabalin is used to reduce neuropathic pain by blocking the pain signals; thus, with the rising burden of neuropathic pain and its risk factors, the demand for pregabalin is expected to grow, propelling growth in the segment over the forecast period. For instance, according to a review study published in February 2022 in Cureus, about 3% to 17% of the general population suffers from neuropathic pain, and neuropathy can contribute to chronic pain and be a component of mixed pain syndromes. Hence, the high burden of patients with neuropathic pain is expected to boost the segment's growth during the forecast period.
Moreover, as per the article published in UpToDate in December 2022, diabetic polyneuropathy was the most common neuropathy across many regions worldwide. Furthermore, approximately 50% of patients with diabetes are expected to eventually develop neuropathy. Therefore, the rising diabetes population, along with the rising diabetic population, is anticipated to drive the segment’s growth.
Therefore, the rising prevalence of diabetes and neuropathic pain is expected to drive the segment’s growth.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is expected to register significant market growth during the forecast period.
The factors driving the growth are attributed to the growing prevalence of epilepsy and related diseases, the rising geriatric population, the strong foothold of key market players, and the availability of pregabalin in the region.
The high prevalence of epilepsy in the United States is anticipated to drive market growth. For instance, according to the National Institute of Neurological Disorders and Stroke data reviewed on April 2023, in the United States, 2.3 million adults and more than 450,000 kids and teenagers suffered from epilepsy, with an estimated 150,000 people receiving an epilepsy diagnosis annually. Such a huge prevalence of epilepsy is anticipated to increase the adoption of pregabalin to reduce abnormal brain activity, driving market growth in the region.
Further, new product approvals in the country and their launches are expected to boost market growth during the forecast period. For instance, in December 2022, the US Food and Drug Administration (USFDA) approved Zydus' Pregabalin Capsules of strength 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. The approval of drugs in the United States is anticipated to contribute to market growth in the region.
Therefore, due to factors such as the rising prevalence of neurological disorders and key initiatives adopted by market players, North America is expected to occupy a significant share of the pregabalin market over the forecast period.
